Statements (105)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
inhibits HE R2 signaling
|
| gptkbp:appointed_by |
gptkb:hospital
antihistamines supportive care intravenous infusion outpatient settings antiemetics adjuvant setting neoadjuvant setting |
| gptkbp:approves |
gptkb:healthcare_organization
gptkb:1998 gptkb:FDA |
| gptkbp:associated_with |
improved prognosis
|
| gptkbp:brand |
gptkb:Herceptin
|
| gptkbp:can_be_used_with |
gptkb:docetaxel
gptkb:paclitaxel gptkb:pertuzumab gptkb:capecitabine chemotherapy |
| gptkbp:caused_by |
hypersensitivity reactions
|
| gptkbp:clinical_trial |
gptkb:trastuzumab-anns
gptkb:trastuzumab-qyyp gptkb:trastuzumab-dttb Phase III |
| gptkbp:combatants |
extracellular domain of HE R2
|
| gptkbp:contraindication |
active infections
severe hypersensitivity |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:established |
tumor growth
|
| gptkbp:growth_rate |
HE R2-positive breast cancer patients
|
| gptkbp:has |
long half-life
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab
|
| gptkbp:includes |
treatment protocols
|
| gptkbp:indication |
gptkb:healthcare_organization
adjuvant therapy neoadjuvant therapy metastatic breast cancer HE R2-positive gastric cancer early-stage breast cancer HE R2-positive breast cancer |
| gptkbp:influences |
immune response
|
| gptkbp:invention |
gptkb:2019
|
| gptkbp:is_associated_with |
improved quality of life
reduced recurrence rates |
| gptkbp:is_available_in |
various formulations
|
| gptkbp:is_available_on |
biosimilars
|
| gptkbp:is_considered |
a breakthrough therapy
a targeted therapy |
| gptkbp:is_evaluated_by |
clinical trials
other cancers |
| gptkbp:is_monitored_by |
cardiac function
|
| gptkbp:is_part_of |
standard of care
HE R2-targeted therapy multimodal treatment strategies |
| gptkbp:is_recognized_by |
medical organizations
|
| gptkbp:is_studied_in |
combination therapies
|
| gptkbp:is_subject_to |
patent laws
|
| gptkbp:is_used_for |
HE R2-positive esophageal cancer
HE R2-positive gastric cancer treatment of HE R2-positive breast cancer |
| gptkbp:is_used_in |
clinical research
adjuvant chemotherapy regimens neoadjuvant chemotherapy regimens |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Herceptin gptkb:Native_American_tribe |
| gptkbp:produced_by |
recombinant DNA technology
|
| gptkbp:provides_information_on |
ASCO guidelines
ESMO guidelines NCCN guidelines |
| gptkbp:requires |
loading dose
|
| gptkbp:research_areas |
gptkb:vaccine
biomarkers clinical trials combination therapy oncology personalized medicine biologics pharmacogenomics targeted therapy patient adherence health economics long-term outcomes real-world evidence drug resistance quality of life studies safety profiles dosing strategies adverse effects monitoring HE R2 testing |
| gptkbp:side_effect |
fatigue
nausea diarrhea infusion reactions cardiotoxicity |
| gptkbp:suitable_for |
pregnancy
severe heart failure |
| gptkbp:targets |
HE R2 protein
|
| gptkbp:used_in |
gptkb:municipality
|
| gptkbp:bfsParent |
gptkb:Perjeta
gptkb:Herceptin |
| gptkbp:bfsLayer |
4
|